ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) insider Alexander Fitzpatrick sold 3,355 shares of the business’s stock in a transaction on Friday, June 12th. The stock was sold at an average price of $10.00, for a total value of $33,550.00. Following the transaction, the insider directly owned 90,910 shares in the company, valued at $909,100. This trade represents a 3.56% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
ARS Pharmaceuticals Stock Performance
Shares of ARS Pharmaceuticals stock opened at $9.76 on Friday. ARS Pharmaceuticals, Inc. has a 52 week low of $6.66 and a 52 week high of $18.90. The business’s fifty day simple moving average is $8.42 and its 200-day simple moving average is $9.33. The firm has a market cap of $969.17 million, a PE ratio of -4.86 and a beta of 0.94. The company has a quick ratio of 4.77, a current ratio of 4.94 and a debt-to-equity ratio of 2.79.
ARS Pharmaceuticals (NASDAQ:SPRY – Get Free Report) last announced its quarterly earnings results on Friday, May 15th. The company reported ($0.61) EPS for the quarter, missing the consensus estimate of ($0.53) by ($0.08). ARS Pharmaceuticals had a negative net margin of 200.00% and a negative return on equity of 153.61%. The business had revenue of $22.68 million during the quarter, compared to analyst estimates of $22.20 million. Equities analysts forecast that ARS Pharmaceuticals, Inc. will post -1.89 earnings per share for the current year.
Institutional Investors Weigh In On ARS Pharmaceuticals
Analysts Set New Price Targets
Several equities analysts have recently commented on the company. Northland Securities assumed coverage on ARS Pharmaceuticals in a research note on Thursday, April 9th. They issued an “outperform” rating and a $25.00 price target on the stock. Weiss Ratings raised ARS Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 1st. Leerink Partners set a $26.00 price target on ARS Pharmaceuticals and gave the company an “outperform” rating in a research note on Tuesday, March 10th. Cantor Fitzgerald upped their price target on ARS Pharmaceuticals from $12.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday, May 28th. Finally, Zacks Research raised ARS Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Wednesday, February 25th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, ARS Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $28.60.
View Our Latest Report on SPRY
About ARS Pharmaceuticals
ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc was founded in 2015 and is headquartered in San Diego, California.
Read More
- Five stocks we like better than ARS Pharmaceuticals
- MarketBeat Week in Review – 06/08 – 06/12
- SpaceX Rings the Bell and Shatters Every Record
- Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story?
- 3 Dividend Stocks Under $50 That Pay You to Wait Out Inflation
Receive News & Ratings for ARS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARS Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
